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and a Bayesian network meta-analysis of log-hazard ratios was performed. The 
primary outcome of the network meta-analysis was the time to progression to Type 
2 diabetes mellitus. Results are presented as hazard ratios and the probabilities of 
treatment rankings. Results: 30 studies were included in the network meta-anal-
ysis. There was a reduced hazard of progression to Type 2 diabetes mellitus associ-
ated with all interventions versus standard care. The most effective interventions 
compared to standard care were diet plus pioglitazone (HR 0.17, 95% CrI [0.09, 0. 
33] ), glipizide (HR 0.16, 95% CrI [0.02, 1.62] ), diet plus exercise plus metformin 
plus rosiglitazone (HR 0.20, 95% CrI [0.11, 0.39] ), diet plus exercise plus orlistat (HR 
0.31, 95% CrI [0.16, 0.61] ) and diet plus exercise plus pedometer (HR 0.35 95% CrI 
[0.11, 1.14] ). The least effective intervention was ramipril (HR 0.91, 95% CrI [0.72, 
1.14] ). ConClusions: Pharmacological and lifestyle interventions are beneficial 
in reducing the risk of progression to Type 2 diabetes mellitus. Lifestyle interven-
tions require significant behaviour changes and this may be achieved through 
incentives such as the use of pedometers. Lifestyle interventions alone, whilst 
beneficial, are unlikely to be as effective as pharmacological interventions alone 
or in combination with lifestyle interventions. Adverse events and costs of 
pharmacological interventions should be taken into account when consider-
ing potential risks and benefits, and their cost-effectiveness relative to lifestyle 
interventions.
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objeCtives: Previous meta-analyses show inconsistent results regarding benefits 
of insulin glargine (GLA) over NPH insulin (NPH) in terms of nocturnal hypogly-
caemia. We analysed standardized efficacy and safety outcomes in uncontrolled 
insulin-naïve subjects with T2DM treated with GLA or NPH according to the oral 
antidiabetic drug (OAD) to which insulin was added (sulfonylurea [SU] ± metformin 
[MET] ). Methods: Patient-level data from 4 Treat-To-Target (TTT) RCTs (FPG < 100 
mg/dL) of ≥ 24 weeks duration were pooled. HbA1c, weight, dose, and hypoglycaemia 
(overall and nocturnal, plasma glucose < 56 mg/dL) were assessed. Results: 2,091 
subjects were analysed; 49% male, mean age 57.8 years. SU-treated subjects had 
longer T2DM duration, higher baseline HbA1c, and were less obese than MET+SU-
treated subjects. Endpoint HbA1c values were similar for GLA and NPH overall (7.4 
vs 7.5%). Subjects adding GLA or NPH to MET+SU had numerically lower weight-
adjusted endpoint insulin doses (GLA 0.40 vs 0.44 U/kg; NPH 0.36 vs 0.42 U/kg), 
with less weight gain (GLA: +1.9 vs +3.7 kg; NPH: +1.8 vs +3.0 kg) versus subjects 
adding insulin to SU. Hypoglycaemia incidence (overall: odds ratio [OR] 0.79 [95% CI 
0.66−0.95]; P= 0.011, nocturnal: OR 0.64 [0.51−0.81]; P< 0.001) and event rates (over-
all: rate ratio [RR] 0.78 [0.65−0.93]; P= 0.006, nocturnal: RR 0.54 [0.42−0.69]; P< 0.001) 
were significantly lower in GLA-treated subjects versus NPH, irrespective of con-
comitant OAD. In general, higher hypoglycaemia incidences/rates were observed 
in the MET+SU groups versus the SU only groups. MET+SU-treated subjects were 
more likely to achieve HbA1c < 7.0% without overall hypoglycemia versus SU-treated 
subjects (GLA: 24.6 vs 16.1%; NPH: 24.2 vs 13.0%). ConClusions: In insulin-naive 
T2DM patients from 4 TTT RCTs, GLA significantly reduced overall and nocturnal 
hypoglycemia risk versus NPH, irrespective of concomitant OAD. Subjects adding 
GLA or NPH to MET+SU had better efficacy outcomes than those adding to SU only, 
with slightly increased hypoglycaemia risk.
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objeCtives: To determine the efficacy and safety of dipeptidyl peptidase-4 (DPP-
4) inhibitors in type 2 diabetes patients according to published data. Methods: 
A systematic review of randomized clinical trials (RCT) in MEDLINE, Cochrane, 
ISI WOK, SCOPUS and clinicaltrials. gov databases was performed. Eligible stud-
ies were RCT with a treatment duration of at least 24 weeks evaluating efficacy 
(HbA1c, fasting plasma glucose-FPG- and weight variation from baseline) and/or 
safety (hypoglycemia rate) of DPP4 inhibitors (linagliptin, saxagliptin, sitagliptin, 
vildagliptin) compared with placebo or non-insulin monotherapy or combination, 
published in English or Spanish until June 2013. A meta-analysis was conducted 
using a random effects model. Standardized mean difference (SMD) for efficacy 
variables and relative risk (RR) for safety variable with 95% confidence intervals 
(CI) were calculated. Results: Of the 4,582 publications retrieved, 3,807 were 
deleted by duplicate review, 581 by title/abstract review and 139 by criteria com-
pliance. Finally, 55 RCT were selected. DPP-4 inhibitor monotherapy was associ-
ated to greater reductions in HbA1c and FPG compared with placebo [SMD= -0.60, 
95% CI= -0.75; -0.46 and SMD= -0.51, 95% CI= -0.62; -0.39, respectively] while com-
pared with metformin the reductions were lower [SMD= 0.28, 95% CI= 0.20; 0.26 
and SMD= 0.36, 95% CI= 0.27; 0.44, respectively]. DPP-4 inhibitors added to met-
formin lowered HbA1c and FPG significantly more than metformin monotherapy 
[SMD= -0.52, 95% CI= -0.62; -0.41 and SMD= -0.41, 95% CI= -0.51; -0.30, respectively], 
and achieved a greater decrease in weight and hypoglycemia risk versus sulfo-
nylurea plus metformin [SMD= -0.55, 95% CI= -0.64; -0.45 y RR= 0.16, 95% CI= 0.11; 
0.21, respectively]. Moreover, the addition of DPP-4 inhibitors to sulfonylurea 
showed a greater reduction in HbA1c compared with sulfonylurea monother-
apy [SMD= -0.54, 95% CI= -0.70; -0.37]. ConClusions: DPP-4 inhibitors added to 
metformin achieved a better glycemic control compared with metformin mono-
Multivariate Cox model adjusted for propensity score and sensitivity analysis 
confirmed a reduced risk of treatment change for M-Sit versus M-SU with a rela-
tive risk of 0.70 [0.62; 0.78] (p< 0.0001). ConClusions: We observed an approxi-
mate two-fold increase in the median treatment maintenance duration in the 
met-Sit group versus the met-SU group. Given the observational design, confound-
ing factors on the primary outcome cannot be excluded. However, multivariate 
and sensitivity analyses showed no qualitative change in the principal finding, 
providing some confidence in the observed difference between the two dual 
therapies.
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objeCtives: To demonstrate the use and interpretation of alternative approaches 
to evaluate and understand inconsistency within network meta-analyses 
(NMA). Methods: A network meta-analysis was performed to compare the efficacy 
of once weekly dulaglutide 1.5mg to licensed doses of liraglutide, exenatide, lixi-
senatide, and albiglutide for the treatment of type 2 diabetes. The primary endpoint 
was reduction in HbA1c. To allow for potential heterogeneity, networks were strati-
fied by background therapy: add-on to metformin (MET) and add-on to metformin in 
combination with sulfonylurea and/or thiazolidinediones (MET±SU±TZD). Networks 
were further stratified by time of evaluation (16-36 weeks and 37-56 weeks). The 
‘node-splitting’ approach and models including treatment-by-design interaction 
effects (where ‘design’ refers to the study comparator set), were used to examine 
inconsistency. Results: For the 37-56 week add-on to MET network there were no 
trials linking to dulaglutide 1.5mg; therefore, a NMA could not be conducted. For the 
37-56 week combination network there were no comparisons for which there were 
both direct and indirect evidence. For the 16-36 week add-on to MET network, there 
were no comparisons with statistically significant inconsistency in HbA1c reduction 
in the node splitting model and no significant design by treatment interactions. For 
the 16-36 week add-on to Met±SU±TZD network there was statistically significant 
variation between the direct and indirect estimates for the comparison between 
glargine and placebo and the comparison between glargine with liraglutide 1.80mg. 
Further sensitivity analyses were conducted removing the LEAD 5 trial (comparing 
placebo, glargine and liraglutide 1.80mg) from the network. ConClusions: The 
node-splitting and treatment-by-design interaction models showed no evidence 
of inconsistency in the 16-36 week monotherapy network. Following removal of 
the LEAD 5 trial, the 16-36 week combination network also showed no evidence of 
inconsistency. The analyses were useful in investigating potential inconsistency 
across the network.
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objeCtives: To evaluate the pattern and clinical outcomes of insulin therapies 
compared to oral antidiabetic therapies in the management of T2DM. Methods: A 
retrospective cohort study of patients with T2DM attending the Mesaimeer Primary 
HealthCare Center in Doha, Qatar. Inclusion criteria included were adult patients 
with at least with T2DM for 12 months period. Exclusion criteria included were age 
below 18 yrs, T2DM history less than 1 year, pregnant women and patients with 
kidney/hepatic disease. Patients’ medical records were reviewed for a period of 
one year. Data collected included socio-demographic profiles, clinical and labora-
tory data, medication regimens, and regimen cost per year. Data were analyzed 
descriptively and using Chi-Square test with priori alpha level of 0.05. Results: A 
total of 295 patients with T2DM attending the primary health center were included 
in the study. Majority of the patients were male (n= 210, 71.2%), age between 25-64 
years old (n= 241, 82.3%) and obese (n= 163, 55.3%). Metformin was the most fre-
quently used oral anti-diabetic medication (89.8%), followed by gliclazide (30.6%) 
and sitagliptin (26.2%). 32.3% of the patients were on insulin at the end of the 12 
month follow-up period. The most common treatment regimen at both time points 
was oral dual therapy (28.3%), followed by oral monotherapy (21.3%) and triple oral 
therapy (20.2%). The mean HbA1c was 8.0+1.6% at both the beginning and end-
point of the 12 month follow-up period, indicating uncontrolled DM. Those patients 
receiving insulin-containing therapy had a significantly higher proportion of uncon-
trolled DM than those who did not receive insulin (98% vs. 81%; p< 0.001) at the 
endpoint of 12-month follow-up period. ConClusions: The findings of this study 
showed that T2DM patients attending primary health care clinics in Qatar were not 
achieving glycemic control.
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objeCtives: Individuals with impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT) have an increased risk of progression to Type 2 diabetes mellitus. 
The objective of this study was to quantify the effectiveness of lifestyle, pharma-
cological and surgical interventions in reducing the progression to Type 2 diabetes 
mellitus in people with IFG or IGT. Methods: A systematic review was carried out 
